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There are large overlaps in cognitive deficits occurring in attention deficit disorder (ADD) and 
neurodevelopmental disorders like neurofibromatosis type 1 (NF1). This overlap is mostly based on 
clinical measures and not on in-depth analyses of neuronal mechanisms. However, the consideration 
of such neuronal underpinnings is crucial when aiming to integrate measures that can lead to a better 
understanding of the underlying mechanisms. Inhibitory control deficits, for example, are a hallmark in 
ADD, but it is unclear how far there are similar deficits in NF1. We thus compared adolescent ADD and 
NF1 patients to healthy controls in a Go/Nogo task using behavioural and neurophysiological measures. 
Clinical measures of ADD-symptoms were not different between ADD and NF1. Only patients with 
ADD showed increased Nogo errors and reductions in components reflecting response inhibition (i.e. 
Nogo-P3). Early perceptual processes (P1) were changed in ADD and NF1. Clinically, patients with ADD 
and NF1 thus show strong similarities. This is not the case in regard to underlying cognitive control 
processes. This shows that in-depth analyses of neurophysiological processes are needed to determine 
whether the overlap between ADD and NF1 is as strong as assumed and to develop appropriate 
treatment strategies.
Inhibitory control processes, required for the prevention of prepotent and inadequate responses, play an impor-
tant role in everyday life1. Dysfunctions in these mechanisms represent a hallmark in attention deficit (hyperac-
tivity) disorder (AD(H)D)2–6. However, ADHD symptoms are also found in other neurodevelopmental disorders, 
like neurofibromatosis type 1 (NF1)7–11. NF1 is a rare monogenetic, autosomal dominant genetic disorder caused 
by mutations in the tumor suppressor gene neurofibromin 1 (17q11.2, MIM*613113) in which a broad spectrum 
of cognitive deficits occur in 30–70% of cases. These mostly appear as learning deficits, attentional deficits, hyper-
activity and language problems7,8,11–13, with full-scale AD(H)D being diagnosed in nearly every second child 
with NF114. Of all symptoms, inattention is predominant in NF115. Several lines of evidence from animal models 
suggest that NF1 is associated with dysfunctional dopaminergic neural transmission16–19, likely leading to deficits 
in attentional selection processes and hyperkinetic symptoms16,17,20. In such animal models, molecular links have 
also been demonstrated between ADHD-like locomotor behaviours, deficient dopaminergic transmission and 
neurofibromin 114. Specifically, NF1 + /−GFAPCKO mice are characterised by reductions in the pre-synaptic 
dopamine transporter and behaviourally show reduced (non-)selective attention16,17. These neurobiological alter-
ations show commonalities with ADHD, and attentional deficits in NF1 can successfully be treated using methyl-
phenidate9,21. Recently, it has also been shown that NF1 is associated with response inhibition deficits22.
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However, until now it is unclear how far response inhibition deficits and their neurophysiological mechanisms 
are comparable between patients with ADHD and those with NF1 and an accompanying ADHD symptomatol-
ogy. Here, based on the pattern of symptomatology, a comparison of patients with NF1 and those with ADD 
(i.e. who are characterised by inattention but not by symptoms of hyperactivity/impulsivity) seems particularly 
useful15. Generally, current knowledge about similarities and differences between ADD and NF1 is mostly based 
on clinical measures of cognitive deficits23, but not on approaches allowing a fine-grained analysis of cogni-
tive subprocesses e.g. combining experimental psychological and neurophysiological approaches. Yet, such an 
approach is of importance, as stressed by the research domain criteria (RDoC) initiative. RDoC is conceived as a 
dimensional system using different units of analysis (e.g. neurophysiology and behavior) that is independent from 
current disorder categories. Its goal is to generate classifications stemming from basic behavioural neuroscience, 
rather than starting with an illness definition and seeking its neurobiological underpinnings24. Concerning cogni-
tive systems, the construct “cognitive control” and the subconstruct “inhibition” is central in neurodevelopmental 
disorders25 and is assumed to represent a relevant RDoC dimension24.
In the current study we therefore examine and compare response inhibition processes at the behavioural and 
neurophysiological level in ADD and NF1. This will provide insights into the nature of each of these disorders 
that have until now not been obtained. At the behavioural level, the rate of false alarms (i.e. responses in situ-
ations where the response has to be inhibited) is the most relevant parameter. At the neurophysiological level, 
different subprocesses from perceptual and attentional selection, to response selection and motor processes can 
be distinguished by examining event-related potentials (ERPs)26,27. Differences and similarities between ADD and 
NF1 may be based in one or several of these stages. Perceptual and attentional selection processes are reflected 
by the P1 and N1 ERPs28–30. Further along the processing cascade, mechanism related pre-motor processes like 
conflict monitoring or updating of the response program (reflected by the Nogo-N2) can be dissociated from 
evaluative processes of the successful outcome of inhibition (reflected by the parietal and central Nogo-P3)26,31–36. 
In the present study we compare adolescent patients with ADD and NF1 to healthy controls in each of the above 
processes to achieve a fine-grained picture of similarities and differences between these disorders in regard to 
response inhibition. This is crucial when aiming to integrate and synthesize measures which can lead to a better 
understanding of the mechanisms and in turn the symptoms to which they relate24. Subsequently, this could trig-
ger the development of putative individualised therapeutic strategies.
Results
Behavioural data. The three groups differed regarding false alarms in Nogo trials (F(2,43) = 5.4; p = 0.008). 
Bonferroni post-hoc testing revealed that patients with ADD committed significantly more false alarms 
(51.8 ± 15.8%) in Nogo trials than healthy controls (31.8 ± 16.5%) (p = 0.003), indicating an inhibition deficit in 
the ADD group. Patients with ADD also committed more Nogo false alarms than those with NF1 (34.8 ± 19.8%) 
(p = 0.03). The difference between the patients with NF1 and the healthy controls was not significant (p = 0.64).
Furthermore, significant differences between the three groups (ADD: 92.9 ± 7.8%, NF1: 90.9 ± 10.3%; con-
trols: 97.9 ± 2.7%) were found concerning the amount of correct responses in Go trials (F(2,43) = 3.9; p = 0.03). 
Bonferroni post hoc tests showed for the differences between the control group and the patients with NF1 to 
be significant (p = 0.01). This was not the case for any of the other comparisons (all p > 0.06). For the reaction 
times on Go trials the NF1 group (491 ± 135 ms) showed significantly slower response than patients with ADD 
(415 ± 55 ms, p = 0.02) and controls (416 ± 89 ms, p = 0.02) (F(2, 43) = 3.4; p = 0.042).
Neurophysiological data. Perceptual categorization (P1) and attentional selection (N1). P1 and N1 com-
ponents are shown in Fig. 1.
Regarding P1 amplitudes, analyses revealed a main effect of Group (F(2, 44) = 4.1; p = 0.02; η p2 = 0.16) as 
well as a trend level interaction of GoNogo*Group (F(2,44) = 2.9, p = 0.06, η p2 = .11). Further univariate analyses 
revealed significantly reduced P1 amplitudes in patients with NF1 (26.9 ± 5.9 μ V/m2) compared to healthy con-
trols (45.9 ± 5.1 μ V/m2, p = 0.02) and patients with ADD (49.2 ± 5.4) μ V/m2, p = 0.01). The difference between 
controls and patients with ADD was not significant (p = 0.66). Further analysis of the trend level interaction of 
GoNogo*Group revealed significant differences between Go (47.3 ± 4.5 μ V/m2) and Nogo trials (42.3 ± 5.1 μ V/m2) 
in healthy controls only (F(1, 16) = 5.3; p = 0.04, η p2 = 0.3). This difference was not significant in patients with 
ADD or NF1 (all F < 1.1; all p > 0.4). Concerning P1 latency, no main effects or interaction were significant (all 
F < 1.9; all p > 0.15; all η p2 < 0.08).
Concerning N1 amplitude, no significant main effects or interactions were found (all F < 2.8; all p > 0.1; all 
η p2 < 0.06). In terms of latency we found a main effect of Group (F(2,44) = 4.2; p = 0.02; η p2 = 0.16). Pair-wise 
comparisons showed that the N1 peak occurred significantly later in patients with NF1 (195 ± 15 ms) than in 
healthy controls (177 ± 16 ms) (p = 0.008). N1 latencies in patients with ADD (188 ± 15 ms) were not significantly 
different to those in patients with NF1 (p = 0.33) or healthy controls (p = 0.06).
Response selection processes (N2 as well as central and parietal P3). N2 and P3 components are shown in Fig. 2.
Analysing the N2 component, we found no main effects or interactions for either amplitude (all F < 0.2; all 
p > 0.66; all η p2 < 0.006) or latency (all F < 2.2; all p > 0.14; all η p2 < 0.05).
Concerning central P3 (cP3) amplitude, we found a main effect of GoNogo (F(1,44) = 8.4, p = 0.006, η p2 = 0.16), 
showing that the cP3peak was generally larger in Nogo (21.2 ± 21.6 μ V/m2) than in Go (amplitude 0.16 ± 19.7 μ V/m2) 
trials. Most importantly, there was an interaction of GoNogo*Group (F(2,44) = 10.9; p < 0.001; η p2 = 0.33). 
Examining this further, we found a main effect of Group in the Nogo trials (F(2,44) = 6.5; p = 0.004), but not in 
the Go trials (F(2,44) = 0.77; p = 0.47). Within the Nogo trials, patients with ADD (amplitude: 9.2 ± 19.2 μ V/m2) 
had a significantly reduced cP3 peak compared to healthy controls (amplitude: 32.5 ± 25.7 μ V/m2) 
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(p = 0.001). The difference between patients with NF1 (amplitude: 21.9 ± 19.3 μ V/m2) and those with ADD was 
also significant (p = 0.02), while this was not the case when comparing them to healthy controls (p = 0.55).
A similar pattern became apparent in regard to cP3 latency, where the interaction of GoNogo*Group was 
also significant (F(2, 44) = 4.1; p = 0.02; η p2 = 0.16). The main effect of Group was significant in the Nogo 
(F(2,44) = 4.2; p = 0.02) but not in the Go trials (F(2,44) = 1.7; p = 0.2). Within the Nogo trials, differences 
between patients with ADD (393 ± 32 ms) and healthy controls (408 ± 30 ms) were not significant (p = 0.3). 
However, the Nogo cP3 peak occurred significantly later in patients with NF1 (latency: 442 ± 49 ms) than was the 
case for patients with ADD (p = 0.007) and healthy controls (p = 0.05).
For the parietal P3 (pP3) (see Fig. 2), we only found a significant main effect of GoNogo (F(2, 44) = 7.7; 
p = 0.008; η p2 = 0.15), with pP3 peaks in Go trials (17.7 ± 3.9 μ V/m2) being generally less pronounced than those 
in Nogo trials (21.9 ± 4.2 μ V/m2). All other main effects and interactions were not significant (all F < 3.5; all 
p > 0.07; all η p2 = 0.08).
Discussion
In the current study we examined behavioural and neurophysiological processes of response inhibition mech-
anisms in a sample of age-matched paediatric patients with ADD and NF1 as well as in healthy controls. The 
goal of this comparison was to evaluate how far ADD and NF1 show distinct and comparable behavioural and 
neurophysiological processes underlying response inhibition and impulsivity. This is important when aiming to 
integrate and synthesize measures which can lead to a better understanding of the mechanisms and in turn of the 
symptoms to which they relate24.
The clinical assessment of ADHD symptoms in both groups using the ADHD Symptom Checklist37 revealed 
that patients with NF1 and those with ADD are highly comparable. Thus, both patients groups fulfil criteria of 
ADD. The in-depth cognitive-neurophysiological assessment, however, revealed a more fine-grained picture. On 
Figure 1. Event-related potentials (ERPs) showing the P1 and N1 component on Go and Nogo trials. The 
scalp topographies show the peak of the amplitudes. Positive values are given in red, negative values are given 
in blue. Time point zero denotes the time point of Nogo stimulus presentation. Negative values are plotted 
downwards. The NF1 patients are shown at the top, the ADD patients in the middle and the control at the 
bottom of the figure.
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the behavioural level, the results show that response inhibition processes are compromised in ADD, but not in 
NF1 when compared to healthy controls. The finding that there was no difference between controls and patients 
with NF1 stands in contrast to other recent results on response inhibition processes in NF122. There are expla-
nations for this. Firstly, in the study by Riberio et al.22 the level of possible ADD symptoms was not assessed and 
the age range of patients was broader. Another explanation for the difference in behavioural findings is that the 
paradigm used by Riberio et al.22 was more difficult, because only one out of nine stimuli was a Nogo stimulus 
and all stimuli were presented at equal frequency. This procedure minimized the possibility that attentional tem-
plates could support task performance. The Nogo task in the present study was easier to perform. It is therefore 
likely that response inhibition deficits in NF1 are less strong compared to those occurring in ADD. This result 
is supported by the neurophysiological data. Here, healthy controls showed the largest Nogo-cP3 amplitudes. 
However, only patients with ADD differed from controls. This was not the case for the patients with NF1. The 
Figure 2. Event-related potentials (ERPs) showing the N2 and P3 component on Go and Nogo trials. The 
scalp topographies show refer to the peak of the amplitudes. Positive values are given in red, negative values are 
given in blue. Time point zero denotes the time point of Nogo stimulus presentation. Negative values are plotted 
downwards. The NF1 patients are shown at the top, the ADD patients in the middle and the control at the 
bottom of the figure. Inlays represent waveforms of the parietal P3 components over PO1 and PO2.
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difference between the two patient groups was significant and cP3 amplitudes in patients with NF1 are thus not 
deficient as in patients with ADD. These differential effects were driven by neurophysiological processes during 
Nogo trials, i.e. mechanisms related to response inhibition. Regarding the N2, no differences between groups 
were evident. This shows that differences between ADD and NF1 are highly specific and affect motor processes 
of response inhibition, but not premotor inhibitory control processes reflected by the Nogo-N2. Several results 
demonstrate that it is specifically the Nogo-P3 which is altered in ADD and ADHD2,3,38–41. Interestingly, it has 
been shown that processes reflected by the Nogo-N2 and Nogo-P3 depend on dissociable dopaminergic systems; 
i.e. the nigrostriatal and dopamine D1 receptor system in case of the Nogo-N2, and the mesocortico-limbic and 
dopamine D2 receptor system in case of the Nogo-P332,42. Especially reduced dopamine D2 turnover is associated 
with a reduced motor inhibition processes and a reduced Nogo-P3 amplitude42. The cognitive-neurophysiological 
results therefore suggest that especially the meso-corticolimbic and/or dopamine D2 receptor system may show 
differences between ADD and NF1. Such possible differences in the catecholaminergic system between ADD and 
NF1, which certainly need to be examined in more detail, may also influence the way in which effects of meth-
ylphenidate on ADD-symptoms in children with NF1 are examined in the future. Although results so far have 
been promising9,21, the knowledge of such possible differential underlying mechanisms may be helpful for the 
optimisation and individualisation of treatment approaches.
Despite these differences between NF1 and ADD at the level of cognitive control, mechanisms of attentional 
selection (cf. N1 ERPs)28 were not differentially modulated between these diseases and were also not different to 
controls. Interestingly, perceptual categorization processes, reflected by the P143 were altered in NF1 and ADD. 
Firstly, P1 amplitudes were generally lower in patients with NF1 compared to the other two groups. Secondly, 
controls clearly show distinct responses between Go and Nogo stimuli. This distinction, however, seemed to be 
almost abolished in patients with ADD and NF1. This perceptual deficit may contribute to the response inhibition 
deficit in ADD. Yet, it does not seem to do so in NF1, because response inhibition performance was not differ-
ent to controls. However, the generally reduced early perceptual processing, which was exclusively observed in 
patients with NF1, could be related to the reduced accuracy in Go trials, which also only occurred in this group. 
This reduced accuracy can, of course, also be explained by the general motor slowing (cf. reaction times) seen in 
NF1 compared to ADD and controls. In response inhibition tasks, it is the speeding of response that emerges due 
to the frequency of Go trials (responses) that makes it hard to inhibit this response44–47. What therefore counts for 
the performance in response inhibition are speeded reactions on Go trials making it hard to inhibit the prepotent 
responses on Nogo trials. Due to the relative slowing of RTs in patients with NF1, response inhibition may thus 
be less demanding. There is a speed-accuracy trade-off in NF1 patients not seen in ADD patients, which may 
explain why response inhibition in NF1 is not as dysfunctional as in ADD. An important clinical implication of 
this finding is that therapeutic attempts to increase motor performance in NF1 may bear the risk that important 
executive control functions are affected negatively. It also needs to be considered how the observed similarities 
and differences between patients with NF1 and those with ADD would change across development from child-
hood to adulthood. Partly based on the maturation of the dopaminergic system during adolescence, only around 
15% of children with ADHD are estimated to also meet full diagnostic criteria at the age of 2548. Based on its 
aetiology, NF1 is a lifelong disorder and neurocognitive deficits have been shown to persist into adulthood49. 
Thus, the magnitude of the differences between ADD and NF1 observed in the current study may even increase 
in adulthood, although specific trajectories remain to be investigated and compared between the two groups as 
well as health controls.
Even though the obtained results are robust, a clear limitation of the study is the limited sample size. The 
study’s results will therefore require replication. Moreover, only one instance of cognitive control processes was 
examined. Other dimensions, e.g. those related to interference control and different aspects of attentional selec-
tion, deserve further detailed investigations. In addition it is important to consider that some of the patients with 
ADD did receive stimulant medication. Sample sizes were not sufficient to differentially consider the effects of 
medication on performance, but previous research50 suggests that P3 amplitudes would potentially have been 
even lower if only medication-naïve patients with ADD had been included in the current study. Nevertheless, this 
is a very important aspect to consider in future investigations. Especially, it would be interesting to examine the 
specific effects of stimulant medication on the neurophysiological correlates of response inhibition in children 
with NF1 and their relation to reported symptom improvements in this patients group9,21.
To summarize, according to standard clinical measures assessing ADD symptoms, both diseases show a 
considerable overlap. However, an in-depth analysis of neurophysiological subprocesses involved in response 
inhibition as an important instance of cognitive control processes provides a more differentiated picture. The 
results show that patients with ADD and NF1 both display dysfunctions in perceptual categorization and that this 
process is additionally generally significantly attenuated in patients with NF1. Yet, aside from this dimension of 
cognitive processes, patients with ADD show response inhibition deficits (compared to controls) which are not 
seen in NF1, despite “impulsivity” being comparable when considering clinical measures. The results suggest 
that clinical measures of symptoms should be complemented by cognitive-neurophysiological approaches. These 
are necessary when aiming to determine whether the overlap between ADD and NF1 is as strong as currently 
assumed and to gain a better understanding of the mechanisms and symptoms to which they relate to inform 
individualized treatment strategies.
Materials and Methods
Samples. All subjects and their parents or legal guardians provided informed written consent according to 
the Declaration of Helsinki and the study was approved by the local ethics committee of the Medical Faculty of 
the TU Dresden.
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N = 13 patients with NF1 were included in the study (9 female, 3 brothers, age 13.5 ± 2.5 years). The NF1 
diagnoses were based on the clinical criteria by the National Institutes of Health (NIH) Consensus Development 
Conference on Neurofibromatosis (NIH, 1988).
N = 16 adolescent patients diagnosed with ADD (1 female, 12.9 ± 3.1 years) according to ICD-10 criteria 
were recruited consecutively into the study from the outpatient clinic. 6 of these patients were taking medication 
(immediate or extended release methylphenidate or atomoxetine). Standard clinical procedures (incl. parent and 
child interview, teacher report, symptom questionnaires, IQ testing, exclusion of potential underlying somatic 
disorders via EEG, EKG, audiometry and vision testing) were used to confirm the diagnosis of ADD. Children 
were only included in the study if they fulfilled diagnostic criteria for ADD.
N = 17 children without ADHD or NF1 were included in the control group (6 female, 13.9 ± 3.4 years). None 
of them were taking medication and none had a psychiatric diagnosis as confirmed by clinical interview. Using 
the ADHD Symptom Checklist37 parents rated (0: no problems, 3: severe problems) their children in regard 
to inattention, hyperactivity and impulsivity. Based on this questionnaire, both patient groups fulfilled criteria 
of ADD according to the ICD-10 criteria (F98.8). Patients with NF1 (1.4 ± 0.8) did not differ from those with 
a confirmed diagnosis of ADD (1.9 ± 0.5) in regard to inattention (p = 0.13). In the hyperactivity dimension 
(ADD: 0.7 ± 0.5; NF1: 0.4 ± 0.6), the impulsivity dimension (ADD: 1.2 ± 0.7; NF1: 1.0 ± 0.9) and in the overall 
score (ADD: 1.2 ± 0.3; NF1: 1.0 ± 0.7), the groups did not differ from each other (all p > 0.48). Age did not differ 
significantly between the groups (p > 0.13). Gender distribution was significantly different between the groups 
(χ 2(2) = 7.2; p = 0.03). To account for this difference, Gender was included as a covariate in all analyses. The 
authors assert that all procedures contributing to this work have been conducted in accordance with the ethical 
standards of the relevant national and institutional committees on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 2008. The study was approved by the local ethics committee of the Medical 
Faculty of the TU Dresden.
Task. We used a standard Go/Nogo task51, which was also used previously to examine response inhibition defi-
cits in ADHD3,52 during the task one out of two words was presented on a monitor: ‘DRÜCK’ (German for ‘PRESS’; 
Go stimulus) and ‘STOP’ (German for ‘STOP’; Nogo stimulus) were presented for 300 ms. Participants were asked 
to respond fast (i.e. within 500 ms) on the ‘DRÜCK’ stimulus and refrain from responding on the ‘STOP’ stimulus. 
The subjects had to react with the right index finger. The inter-trial interval (ITI) was jittered between 1600 ms and 
1800 ms. The experiment consisted of 248 Go trials and 112 Nogo trials presented in a pseudo-randomized order 
to avoid consecutive identical trial conditions. The task lasted approximately 20 minutes.
EEG recording and analyses. The EEG was recorded from 60 Ag/AgCl electrodes (500 Hz sampling rate). 
Electrode impedances were kept below 5 kΩ . The reference electrode was located at Fpz and the ground electrode 
was located at θ = 58, ф = 78. During off-line data processing, the data were down-sampled to 256 Hz. Afterwards, 
a band-pass filter from 0.5 to 20 Hz (slope of 48 db/oct) was applied. After removing technical artifacts, period-
ically occurring artifacts (pulse artifacts, horizontal and vertical eye movements) were detected and corrected 
for by means of an independent component analysis. Then, the EEG was segmented to the onset of the Go and 
Nogo stimuli. Only trials with correct responses on Go and without responses on Nogo trials were considered. 
Segments started 200 ms before and ended 1500 ms after stimulus onset. An automated artefact rejection proce-
dure was applied containing an amplitude criterion (maximal amplitude: 200 μ V, minimal amplitude: − 200 μ V) 
and using a maximal value difference of 200 μ V in a 200 ms interval as well as an activity below 0.5 μ V in a 
100 ms period as rejection criteria. Next, a current source density (CSD) transformation was run to obtain a 
reference-free evaluation of the EEG data which helps to find the electrodes showing the strongest effects53. A 
baseline correction was then set to a time interval from − 200 ms to 0 ms before the segments were averaged for 
each condition. For ERP quantification the following electrodes were chosen on the basis of the scalp topography. 
Single-subject ERP-amplitudes were quantified semi-automatically as the most positive/negative peak (amplitude 
and latency) within a defined time interval: The P1 peak was measured over pooled electrodes P7, P8, P9 and P10 
in the time window of 90–120 ms post-stimulus. The N1 peak was quantified over the same electrodes in the time 
window of 165–205 ms after the stimulus. Electrodes FCz and Cz were pooled and then used to measure the N2 
(250–330 ms) and central P3 peaks (cP3, 380–430 ms). To account for parietal P3 components (pP3) which espe-
cially occur in Go trials and shift towards more anterior regions in Nogo trials (central P3)26,54, we also examined 
activation at electrodes PO1 and PO2 in the time window of 330–350 ms. As no clear peak was discernible in the 
visual inspection of the data in case of the pP3, an area export was performed instead of a peak detection. This 
choice of electrodes and time windows was validated using a statistical procedure described in ref. 55.
Statistics. Behavioural data were analyzed using univariate ANOVAs and t-tests. The neurophysiological 
data were analyzed by means of mixed effects ANOVAs using the within-subject factor Condition (Go vs. Nogo) 
and the between-subjects factor Group (NF1 vs. ADD vs. controls). P1 and N1 components were analysed over 
electrodes P7, P8, P9 and P10 (pooled together). P2, N2 and cP3 were quantified at electrodes Cz and FCz (pooled 
together). pP3 was examined at electrodes PO1 and PO2 (pooled together). Greenhouse-Geisser correction was 
applied and post-hoc tests were bonferroni-corrected when necessary. To account for differences in gender distri-
bution between the three groups, Gender was included as a covariate in all analyses. All variables were normally 
distributed as indicated by Kolmogorov-Smirnov tests (all z < 1.05; p > 0.2).
Ethical standards. The authors assert that all procedures contributing to this work have been conducted in 
accordance with the ethical standards of the relevant national and institutional committees on human experimen-
tation and with the Helsinki Declaration of 1975, as revised in 2008. The study was approved by the local ethics 
committee of the Medical Faculty of the TU Dresden.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:43929 | DOI: 10.1038/srep43929
References
1. Diamond, A. Executive functions. Annu. Rev. Psychol. 64, 135–168 (2013).
2. Albrecht, B. et al. Familiality of neural preparation and response control in childhood attention deficit-hyperactivity disorder. 
Psychol. Med. 43, 1997–2011 (2013).
3. Bluschke, A., Roessner, V. & Beste, C. Specific cognitive-neurophysiological processes predict impulsivity in the childhood 
attention-deficit/hyperactivity disorder combined subtype. Psychol. Med. 46, 1277–1287 (2016).
4. Coghill, D. R., Hayward, D., Rhodes, S. M., Grimmer, C. & Matthews, K. A longitudinal examination of neuropsychological and 
clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): improvements in executive functioning do not 
explain clinical improvement. Psychol. Med. 44, 1087–1099 (2014).
5. Coghill, D. R., Seth, S. & Matthews, K. A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making 
and variability in attention deficit hyperactivity disorder: advancing beyond the three-pathway models. Psychol. Med. 44, 1989–2001 
(2014).
6. Kenemans, J. L. et al. Attention deficit and impulsivity: selecting, shifting, and stopping. Int. J. Psychophysiol. Off. J. Int. Organ. 
Psychophysiol. 58, 59–70 (2005).
7. Ferner, R. E., Hughes, R. A. & Weinman, J. Intellectual impairment in neurofibromatosis 1. J. Neurol. Sci. 138, 125–133 (1996).
8. Kayl, A. E. & Moore, B. D. Behavioral phenotype of neurofibromatosis, type 1. Ment. Retard. Dev. Disabil. Res. Rev. 6, 117–124 
(2000).
9. Lidzba, K., Granstroem, S., Leark, R. A., Kraegeloh-Mann, I. & Mautner, V.-F. Pharmacotherapy of attention deficit in 
neurofibromatosis type 1: effects on cognition. Neuropediatrics 45, 240–246 (2014).
10. Lidzba, K., Granström, S., Lindenau, J. & Mautner, V.-F. The adverse influence of attention-deficit disorder with or without 
hyperactivity on cognition in neurofibromatosis type 1. Dev. Med. Child Neurol. 54, 892–897 (2012).
11. North, K. N. et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 
Cognitive Disorders Task Force. Neurology 48, 1121–1127 (1997).
12. Barton, B. & North, K. Social skills of children with neurofibromatosis type 1. Dev. Med. Child Neurol. 46, 553–563 (2004).
13. Mautner, V.-F., Granström, S. & Leark, R. A. Impact of ADHD in adults with neurofibromatosis type 1: associated psychological and 
social problems. J. Atten. Disord. 19, 35–43 (2015).
14. van der Voet, M., Harich, B., Franke, B. & Schenck, A. ADHD-associated dopamine transporter, latrophilin and neurofibromin 
share a dopamine-related locomotor signature in Drosophila. Mol. Psychiatry 21, 565–573 (2016).
15. Pride, N. A., Payne, J. M. & North, K. N. The Impact of ADHD on the Cognitive and Academic Functioning of Children With NF1. 
Dev. Neuropsychol. 37, 590–600 (2012).
16. Brown, J. A., Diggs-Andrews, K. A., Gianino, S. M. & Gutmann, D. H. Neurofibromatosis-1 heterozygosity impairs CNS neuronal 
morphology in a cAMP/PKA/ROCK-dependent manner. Mol. Cell. Neurosci. 49, 13–22 (2012).
17. Brown, J. A. et al. PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp. Neurol. 232, 333–338 
(2011).
18. Diggs-Andrews, K. A. et al. Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann. Neurol. 73, 309–315 
(2013).
19. Diggs-Andrews, K. A. & Gutmann, D. H. Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci. 36, 237–247 
(2013).
20. Wozniak, D. F. et al. Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. PloS One 
8, e66024 (2013).
21. Mautner, V.-F., Kluwe, L., Thakker, S. D. & Leark, R. A. Treatment of ADHD in neurofibromatosis type 1. Dev. Med. Child Neurol. 
44, 164–170 (2002).
22. Ribeiro, M. J., Violante, I. R., Bernardino, I., Edden, R. A. E. & Castelo-Branco, M. Abnormal relationship between GABA, 
neurophysiology and impulsive behavior in neurofibromatosis type 1. Cortex J. Devoted Study Nerv. Syst. Behav. 64, 194–208 (2015).
23. Miguel, C. S., Chaim-Avancini, T. M., Silva, M. A. & Louzã, M. R. Neurofibromatosis type 1 and attention deficit hyperactivity 
disorder: a case study and literature review. Neuropsychiatr. Dis. Treat. 11, 815–821 (2015).
24. Insel, T. et al. Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders. Am. 
J. Psychiatry 167, 748–751 (2010).
25. Chmielewski, W. X. & Beste, C. Action control processes in autism spectrum disorder--insights from a neurobiological and 
neuroanatomical perspective. Prog. Neurobiol. 124, 49–83 (2015).
26. Huster, R. J., Enriquez-Geppert, S., Lavallee, C. F., Falkenstein, M. & Herrmann, C. S. Electroencephalography of response inhibition 
tasks: Functional networks and cognitive contributions. Int. J. Psychophysiol. 87, 217–233 (2013).
27. Stock, A.-K., Popescu, F., Neuhaus, A. H. & Beste, C. Single-subject prediction of response inhibition behavior by event-related 
potentials. J. Neurophysiol. jn.00969.2015 (2015). doi: 10.1152/jn.00969.2015
28. Herrmann, C. S. & Knight, R. T. Mechanisms of human attention: event-related potentials and oscillations. Neurosci. Biobehav. Rev. 
25, 465–476 (2001).
29. Schneider, D., Beste, C. & Wascher, E. On the time course of bottom-up and top-down processes in selective visual attention: an EEG 
study. Psychophysiology 49, 1492–1503 (2012).
30. Beste, C., Baune, B. T., Falkenstein, M. & Konrad, C. Variations in the TNF-α gene (TNF-α − 308G → A) affect attention and action 
selection mechanisms in a dissociated fashion. J. Neurophysiol. 104, 2523–2531 (2010).
31. Beste, C., Ness, V., Falkenstein, M. & Saft, C. On the role of fronto-striatal neural synchronization processes for response 
inhibition–evidence from ERP phase-synchronization analyses in pre-manifest Huntington’s disease gene mutation carriers. 
Neuropsychologia 49, 3484–3493 (2011).
32. Beste, C., Willemssen, R., Saft, C. & Falkenstein, M. Response inhibition subprocesses and dopaminergic pathways: basal ganglia 
disease effects. Neuropsychologia 48, 366–373 (2010).
33. Beste, C., Dziobek, I., Hielscher, H., Willemssen, R. & Falkenstein, M. Effects of stimulus-response compatibility on inhibitory 
processes in Parkinson’s disease. Eur. J. Neurosci. 29, 855–860 (2009).
34. Falkenstein, M., Hoormann, J. & Hohnsbein, J. ERP components in Go/Nogo tasks and their relation to inhibition. Acta Psychol. 
(Amst.) 101, 267–291 (1999).
35. Nieuwenhuis, S., Yeung, N., van den Wildenberg, W. & Ridderinkhof, K. R. Electrophysiological correlates of anterior cingulate 
function in a go/no-go task: effects of response conflict and trial type frequency. Cogn. Affect. Behav. Neurosci. 3, 17–26 (2003).
36. Ramautar, J. R., Kok, A. & Ridderinkhof, K. R. Effects of stop-signal probability in the stop-signal paradigm: the N2/P3 complex 
further validated. Brain Cogn. 56, 234–252 (2004).
37. Döpfner, M., Görtz-Dorten, A. & Lehmkuhl, G. Diagnostik-System für Psychische Störungen im Kindes- und Jugendalter nach ICD-10 
und DSM-IV, DISYPS-II. (Huber, 2008).
38. Cheung, C. H. M. et al. Cognitive and neurophysiological markers of ADHD persistence and remission. Br. J. Psychiatry J. Ment. Sci. 
208, 548–555 (2016).
39. Liotti, M., Pliszka, S. R., Higgins, K., Perez, R. & Semrud-Clikeman, M. Evidence for specificity of ERP abnormalities during 
response inhibition in ADHD children: a comparison with reading disorder children without ADHD. Brain Cogn. 72, 228–237 
(2010).
www.nature.com/scientificreports/
8Scientific RepoRts | 7:43929 | DOI: 10.1038/srep43929
40. Pliszka, S. R. et al. Electrophysiological effects of stimulant treatment on inhibitory control in children with attention-deficit/
hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 17, 356–366 (2007).
41. Tye, C. et al. Attention and inhibition in children with ASD, ADHD and co-morbid ASD + ADHD: an event-related potential study. 
Psychol. Med. 44, 1101–1116 (2014).
42. Beste, C., Stock, A.-K., Epplen, J. T. & Arning, L. Dissociable electrophysiological subprocesses during response inhibition are 
differentially modulated by dopamine D1 and D2 receptors. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 26, 
1029–1036 (2016).
43. Klimesch, W. Evoked alpha and early access to the knowledge system: the P1 inhibition timing hypothesis. Brain Res. 1408, 52–71 
(2011).
44. Bari, A. & Robbins, T. W. Inhibition and impulsivity: behavioral and neural basis of response control. Prog. Neurobiol. 108, 44–79 
(2013).
45. Dippel, G., Chmielewski, W., Mückschel, M. & Beste, C. Response mode-dependent differences in neurofunctional networks during 
response inhibition: an EEG-beamforming study. Brain Struct. Funct. (2015). doi: 10.1007/s00429-015-1148-y
46. Helton, W. S., Kern, R. P. & Walker, D. R. Conscious thought and the sustained attention to response task. Conscious. Cogn. 18, 
600–607 (2009).
47. Quetscher, C. et al. Striatal GABA-MRS predicts response inhibition performance and its cortical electrophysiological correlates. 
Brain Struct. Funct. 220, 3555–3564 (2015).
48. Faraone, S. V., Biederman, J. & Mick, E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of 
follow-up studies. Psychol. Med. 36, 159–165 (2006).
49. Costa, D. de S. et al. Neuropsychological impairments in elderly Neurofibromatosis type 1 patients. Eur. J. Med. Genet. 57, 216–219 
(2014).
50. Janssen, T. W. P. et al. A Randomized Controlled Trial Investigating the Effects of Neurofeedback, Methylphenidate, and Physical 
Activity on Event-Related Potentials in Children with Attention-Deficit/Hyperactivity Disorder. J. Child Adolesc. Psychopharmacol. 
(2016). doi: 10.1089/cap.2015.0144
51. Bluschke, A., Broschwitz, F., Kohl, S., Roessner, V. & Beste, C. The neuronal mechanisms underlying improvement of impulsivity in 
ADHD by theta/beta neurofeedback. Sci. Rep. 6, 31178 (2016).
52. Chmielewski, W. X., Mückschel, M., Roessner, V. & Beste, C. Expectancy effects during response selection modulate attentional 
selection and inhibitory control networks. Behav. Brain Res. 274, 53–61 (2014).
53. Nunez, P. L. & Pilgreen, K. L. The spline-Laplacian in clinical neurophysiology: a method to improve EEG spatial resolution. J. Clin. 
Neurophysiol. Off. Publ. Am. Electroencephalogr. Soc. 8, 397–413 (1991).
54. Bokura, H., Yamaguchi, S. & Kobayashi, S. Electrophysiological correlates for response inhibition in a Go/NoGo task. Clin. 
Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol. 112, 2224–2232 (2001).
55. Mückschel, M., Stock, A.-K. & Beste, C. Psychophysiological mechanisms of interindividual differences in goal activation modes 
during action cascading. Cereb. Cortex N. Y. N 1991 24, 2120–2129 (2014).
Acknowledgements
This work was supported by a Grant from the Else Kröner-Fresenius Stiftung (2014_A46) and by the Friede 
Springer Stiftung (033/2017). We thank all participants and are grateful to Benjamin Teufert for his help with the 
figures. We acknowledge support by the German Research Foundation and the Open Access Publication Funds 
of the TU Dresden.
Author Contributions
Study design: A.B., M.v.d.H. & C.B., data collection and analysis: A.B. & K.P., writing of the manuscript: A.B. & 
C.B., reviewing of the manuscript: M.v.d.H., V.R. & C.B.
Additional Information
Competing Interests: A.B., M.v.d.H. and K.P. declare no competing or potential conflicts of interest. V.R. has 
received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture 
honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire 
and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, 
Shire, and Otsuka companies. C.B. has received payment for consulting from GlaxoSmithKline, and Teva.
How to cite this article: Bluschke, A. et al. Response inhibition in Attention deficit disorder and 
neurofibromatosis type 1 – clinically similar, neurophysiologically different. Sci. Rep. 7, 43929; doi: 10.1038/
srep43929 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2017
